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Abstract
Purpose: This retrospective study was undertaken to clarify the role of high energy external beam radiation therapy (EBRT) and to
determine its safety and efficacy on local control and visual acuity in patients suffering from choroidal metastases (CM).
Materials and methods: The records of 58 consecutive patients treated with EBRT between 1970 and 1993 were analyzed. The female to
male ratio was 2.9 and the median age was 59 years (range 40–81 years). Thirty-six patients (62%) had unilateral CM and 22 patients had
bilateral CM. The mean number of lesions per eye was two. Retinal detachment was present in 65% of cases. The primary tumour (PT) was
breast carcinoma for 38 patients (75%), lung carcinoma for 10 patients (17%) and gastrointestinal, genitourinary or unknown PT for the
remaining 10 patients. The median interval of time between the PT and the CM was 55 months (range 0–228 months). All patients were
treated with megavoltage irradiation. The median prescribed dose was 35.5 Gy (range 20–53 Gy) normalized at a 2 Gy per fraction
schedule with an a/b value of 10 Gy. Various techniques were used and whenever possible the lens was spared. Ten patients with unilateral
disease were treated in both eyes.
Results: The tumour response was slow. When assessed after 3 months or more, the complete response rate was 53% with significantly
better results for doses higher than 35.5 Gy (72 versus 33%; P = 0.009). Visual acuity was improved or stabilized in 62% of patients, with
also significantly better results when doses higher than 35.5 Gy (P = 0.014) were administered. Amongst 26 patients with unilateral CM
who had no elective contralateral irradiation, three developed metastasis in the opposite eye versus none of the 10 patients who had bilateral
irradiation. Five complications occurred (three cataracts, one retinopathy and one glaucoma).
Conclusion: Radiation therapy is an efficient and safe palliative treatment for choroidal metastases and it helps the preservation of vision.
Thus, there is a major impact on the quality of life in a group of patients with an almost uniformly fatal prognosis. Both tumour response
and visual acuity are significantly improved if doses higher than 35.5 Gy are administered. Whenever possible, a lens sparing technique
should be used. Ó 1998 Elsevier Science Ireland Ltd.
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1. Introduction
Choroidal metastases (CM) are the most common intrao-
cular neoplasms. Bloch and Gartner [3] examined the eye
and orbit post-mortem in 230 cancer patients and found 28
eyes with metastases, with an overall incidence of 12%.
Nelson et al. [11] similarly found a 9% incidence of intrao-
cular metastases in 716 eyes [11]. However, the incidence of
clinically symptomatic intraocular secondary tumours is
lower. Albert et al. [1] in the 1960s estimated it to be
2.3%. The uveal tract is the most common site of intraocular
metastases, probably due to anatomical reasons and blood
vessel supply. With the improvement in cancer treatment
and prolongation of survival, it is likely that more and more
patients will present symptomatic choroidal metastases. As
a result, the most common symptom, decreased vision, can
have major repercussions on the quality of live of those
patients who are generally in a poor physical condition. In
this study, we retrospectively analyzed all consecutive
patients with uveal metastases treated by external beam
radiation therapy in our institution, in order to assess the
safety and efficacy of the treatment.
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2. Materials and methods
The records of 58 consecutive patients admitted in the
Radiation Oncology Department of the Centre Hospitalier
Universitaire Vaudois (CHUV) in Lausanne for treatment of
CM between 1970 and 1993 were reviewed. The majority of
these patients as well as the majority of follow-up examina-
tions were at the Hoˆpital Ophtalmique Jules Gonin, Univer-
sity of Lausanne. All information regarding the date and site
of the primary, tumour local status of the primary at the time
when CM was diagnosed, date of CM diagnosis, symptoms,
localization and number of lesions in the eye, radiation
treatment and technical parameters was collected. To eval-
uate the treatment results, all the ophthalmologic clinical
observations were gathered, as well as the date and localiza-
tion of any new metastasis and the date of death.
The main study end-points were clinical response, visual
improvement, retinal reattachment and postradiation ocular
complications. Survival analysis was also performed to
determine the overall prognosis of this particular patient
population.
2.1. Patient characteristics
Of the 58 patients, 43 were female and 15 were male
giving a sex ratio of 2.9. The ages ranged from 40 to 81
years, with a median of 59 years (Table 1).
2.2. Primary tumour characteristics
The primary tumour characteristics are summarized in
Table 1. Most of the patients presented primary breast can-
cer (38/58) or lung cancer (10/58), while the remainder were
primary prostate, kidney, oesophagus, stomach, rectum car-
cinoma, unknown primary and retroperitoneal soft tissue
sarcoma. Histology was mainly adenocarcinoma (50/58),
while two patients presented with squamous cell carcinoma,
two patients presented with small cell carcinoma, one
patient presented with clear cell carcinoma, one patient pre-
sented with signet cell carcinoma and one patient presented
with leiomyosarcoma. Of note is the fact that the CM was
the first clinical manifestation of cancer disease for eight
patients. The median time between CM and the discovery of
the primary tumour was 55 months (range 0–228 months).
The time interval was much shorter for lung cancer (2.5
months) than for breast cancer (68 months).
In half of the patients the primary cancer was locally
controlled at the time of CM diagnosis.
2.3. Choroidal metastases characteristics
Altogether, 80 eyes in 58 patients were affected by metas-
tases. For 36 patients (62%) CM were unilateral with an
equal distribution between the right and the left side and
for 22 patients (38%) CM were bilateral. The posterior pole
of the choroid was affected in 53 eyes (66%), the iris in
three cases (4%), and in the remaining 24 eyes, the CM
were localized in the periphery of the choroid. In nine
cases the lesion infiltrated the ciliary body.
In half of the eyes the metastasis was solitary, while in the
remainder the number of metastases varied from two to
eight. Table 2 shows the number of CM considering eye
side and primary. Retinal detachment was present in 50
eyes.
Table 3 describes the frequency of symptoms, blurred
vision being the most commonly encountered. The diagno-
sis of CM was made on the basis of clinical examination in
most cases and was confirmed by fluorescein angiography
and ultrasonography, except for one case where it was
obtained by needle biopsy. Fourteen patients with 21
involved eyes were unsuccessfully treated prior to irradia-
tion with various modalities (chemotherapy, 12 eyes;
hormonal therapy, seven eyes; photocoagulation, two
eyes).
Table 1
Age and time to choroidal metastasis since diagnosis of primary tumour







Male 15 61 (48–70) 12 (0–62)
Female 43 55 (40–81) 68 (0–228)
Breast cancerb 38 56 (40–81) 68 (0–228)
Lung cancer 10 61 (48–75) 2.5 (0–40)
Other primary 13 61 (44–81) 11 (0–108)
aThree patients had double primary localization.
bIn addition five women had bilateral breast cancer.
Table 2






1 2 3 4 5 >5
Breast 52 26 10 4 6 5 1
Lung 13 8 2 1 0 0 2
Others 15 5 3 0 5 0 2
Right eye 40 20 8 2 6 2 2
Left eye 40 19 7 3 5 3 3
Table 3
Symptoms and frequency in choroidal metastases presentation
Symptoms No. of
patients (%)
Blurred vision 53 (91)
Visual field defect 13 (22)
Photopsia, xanthopsia 9 (15)
Metamorphopsia 7 (12)
Inflammation (red eye) 2 (3)
Visible tumour, iris lesion 2 (3)
Pain 1 (1)
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2.4. Treatment
Altogether, 88 eyes were irradiated by EBRT with 6 MV
photons or electron beams of various energies. Of the 80
eyes actually affected with metastases, 78 were irradiated
and two were not, in one case because of prior enucleation
and in the other one for an unknown reason. Thus, the
remaining 10 treated eyes, which were not affected, could
be considered as being irradiated electively.
During the observed period of time, the irradiation tech-
niques varied substantially, i.e. the eyes were treated either
by one lateral, oblique or anterior field, or by two lateral or
crossed fields. For further analysis, we grouped the different
techniques as follows: (1) bilateral irradiation with two lat-
eral fields, (a) with or (b) without a lens-sparing technique;
(2) unilateral irradiation (a) with or (b) without a lens-spar-
ing technique (Table 4). The doses varied from 20 to 53 Gy
in 10–30 fractions. For the purpose of this analysis, doses
were normalized to 2 Gy per fraction equivalent, using the
linear-quadratic model with an a/b value of 10 Gy. This
large variation of techniques and doses was essentially
due to changes in the medical teams and policy of treatment
during a 23-year period.
Response to treatment was defined as (1) tumour shrink-
age: (a) complete response (CR), complete tumour shrink-
age replaced by a scar; (b) partial response (PR), less than
complete shrinkage of tumour with scar formation; (c) no
change (NC), no change in tumour volume; (d) progressive
disease (PD), increase in tumour volume; (2) improvement
of vision: (a) visual acuity improved or stable; (b) visual
acuity worse than before treatment; (3) retinal reattachment:
(a) CR, complete reattachment; (b) PR, any detectable reat-
tachment; (c) NC, no change in detachment; (d) PD,
increase in detachment of retina.
2.5. Statistical methods
Survival was estimated by the Kaplan–Meier method [9]
and standard errors of survival were estimated by the Green-
wood formula [5]. All patients were included in the analysis
and potential losses of follow-up were considered as cen-
sored observations at the date of last known survival. Sur-
vival differences were tested by the log-rank test [13].
Differences in distributions of clinical response and vision
were tested by the x2-test [2]. The cumulative incidence of
competing events (death, complication and others metas-
tases) for the event-free survival was estimated by appro-
priate methodology [8].
3. Results
3.1. Response to treatment
The majority of eyes achieved a complete disappearance
or at least a detectable shrinkage of the tumour mass. Only
three of 67 eyes (14 eyes were never evaluated after treat-
ment) presented no change or progression of the tumour
mass and thus CR and PR were achieved in 53 and 29%
of cases, respectively. When we compare treatment results
for two dose levels (more than 35.5 Gy versus less than 35.5
Gy), CR was achieved in 72 and 33%, and PR was achieved
in 18 and 41% of cases, respectively. This difference in CR
according to dose was highly significant (P = 0.009). Visual
improvement or stabilization was achieved in 62% of eyes.
Again, visual improvement was significantly better when
higher doses (.35.5 Gy) were applied, i.e. 72 versus 51%
(P = 0.014). The rate of complete retinal reattachment was
32% and the rate of partial reattachment was 22%. For this
particular end-point, no dose response could be demon-
strated (P = 0.457) (Table 5).
It is quite interesting to note that the response to the
treatment was delayed with time. For almost all the patients
who were examined within 6 weeks after treatment and then
re-examined at or after 3 months, we observed an improve-
ment in response and for only one patient did we observe















Bilateral irradiation 21a 9 30 60
Unilateral irradiation 18b 10 28 28
Total 39 19 58 88
aIncludes 10 patients with unilateral choroidal metastases.
bIncludes two patients with bilateral choroidal metastases irradiated on one
side (see text).
Table 5











Overall 11 41 (53) 23 (29) 3 (4)
,35.5 Gy 8 13 (33) 16 (41) 2 (5)
.35.5 Gy 3 28 (72) 7 (18) 1 (2) 0.009
Retinal reattachment
Overall 18 16 (32) 11 (22) 5 (10)
,35.5 Gy 11 6 (22) 7 (26) 3 (11)




Overall 19 48 (62) 11 (14)
,35.5 Gy 15 20 (51) 4 (10)
.35.5 Gy 4 28 (72) 7 (18) 0.014
See text for definition of responses.
aFor some patients data were available, for example, for vision, whereas
retinal reattachment or tumour shrinkage were not assessed.
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3.2. Complication
Five radiation-induced complications were noted during
the follow-up period at doses of 36.5, 51.4, 52.0, 44.0 and
32.5 Gy (normalized at a 2 Gy per fraction schedule with an
a/b value of 10 Gy) after 0.5, 0.5, 1.5, 3.5 and 3.5 years,
respectively, following treatment (Fig. 3).
There were three cataracts, one radiation-induced retino-
pathy and one glaucoma. The one case of glaucoma was due
to subretinal haemorrhage and the patient needed enuclea-
tion 8 months after treatment. Radiation-induced retinopa-
thy was observed in a patient who underwent fine needle
biopsy for diagnosis. None of the patients who presented a
cataract underwent phakectomy. We did not observe any
case of dry eye syndrome.
As previously mentioned, 10 eyes without CM were elec-
tively irradiated and none developed any new CM during
the follow-up period. Conversely, among the 26 healthy
contralateral eyes which were not electively irradiated,
three had new metastases. We did not observe any compli-
cation in any of the healthy eyes after irradiation.
3.3. Survival
The overall 1-, 2- and 3-year survival rates after CM
diagnosis for the entire group of patients were 47, 19 and
10%, respectively. For the breast cancer group, they were
59, 30 and 19% and for the lung cancer group they were 20,
7 and 0%, respectively. The difference according to the
primary tumour localization was significant (P = 0.018)
(Figs. 1 and 2).
The cumulative incidence of competing events such as
death, extra-ocular metastases and complication is shown in
Fig. 3. At 1 year the cumulative incidence of complication
remains low (,10%).
4. Discussion
As described in previous series, our data confirm that CM
are mostly seen in a female population with primary breast
cancer, the second most frequent primary tumour being lung
cancer [1,3,6,15,21].
According to some hypotheses, the higher incidence of
CM in patients with breast cancer could be due to a greater
affinity of this tumour type to the eye tissue. However, the
median time from PT to the diagnosis of CM was much
shorter for lung cancer patients (2.5 months) than for breast
cancer patients (68 months). Thus, the higher incidence may
simply reflect the longer natural history of breast cancer. As
a matter of curiosity, there were 34 women and four men
with CM from breast cancer with a female to male ratio of
8.5. In general the sex ratio in breast cancer is around 100:1
(M/F).
Some authors suggest that multiple CM is specific for
patients with breast cancer [19], but in our series multiple
lesions were present regardless of the primary tumour site.
As reported by others, the predominant histologic type of
the PT in our study was adenocarcinoma [1].
The typical presentation of a CM is a homogeneous
creamy yellow choroidal lesion, which is often complicated
by secondary retinal detachment. The differential diagnosis
with ocular melanoma or other ocular lesions can be made
Fig. 1. Overall survival since radiotherapy for the entire group.
Fig. 2. Overall survival since radiotherapy according to PT.
Fig. 3. Cumulative incidence for death, new extra-ocular metastasis and
complication in the eye after treatment.
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by clinical evaluation, including a previous cancer history,
ophthalmoloscopic examination, ultrasonography, compu-
ter tomography and fluorescein angiography. Some investi-
gators advocate needle aspiration biopsy to improve the
diagnosis [14,17]. We feel, however, that it should only
be done in very exceptional and difficult diagnostic situa-
tions because of a significant risk of a seeding along the
biopsy track, which may preclude efficient radiotherapy or
cause other complications.
Chu et al. [4], in their analysis of CM of breast cancer,
divided the choroidal lesions into three grades according to
the severity of the retinal detachment and extent of the
lesion. This type of analysis was not possible in our work
because of the wide variation in the size of metastases with
or without retinal detachment. In addition, the methods of
measurements changed during the period of this analysis; in
the 1970s the size was reported according to the surface of
the lesions, whereas current measurements also take thick-
ness into account. For this reason we could not make any
dose–volume response assessments.
In previously published analyses, the effect of radiation
therapy on CM was assessed only on the basis of subjective
or objective visual improvement [7,10,15,16,19,20]. Hoo-
genhout et al. [6] reported their results both in terms of
visual improvement and tumour regression or retinal reat-
tachment.
Our data allows us to separately analyze tumour shrink-
age, retinal reattachment and preservation of vision. Even if
the mechanism of retinal reattachment is quite complex, we
feel that irradiation plays a major role. It should be empha-
sized that after irradiation of CM, the lesions become pro-
gressively flatter, with a typical pigment epithelial
proliferation over the surface of the lesions [10]. This par-
tially atrophic surface is considered as a ‘scar’, which can
even be larger than the metastasis prior to treatment. This
particular phenomenon allows a better retrospective esti-
mate of the real initial surface of CM. If all patients who
underwent an ophthalmological re-evaluation are taken into
account, our data show that with EBRT, the overall response
rate is 96% and the complete response rate is 61%. Regard-
ing retinal reattachment, the overall reattachment rate is
84% and the complete reattachment rate is 50%. However,
this corresponds to the patients’ ophthalmological status at
the last visit. It is possible that the proportion of patients
who had incomplete or no retinal reattachment and who
could not come for their next visit actually improved their
eyes’ status. It is then possible that our data underestimate
the overall reattachment rate. Vision was improved or was
stabilized in 81% of the eyes. Results were significantly
better when total doses were higher than 35.5 Gy. The num-
ber of patients was too small to analyze the treatment
response according to primary site. In two patients of this
series, no response to EBRT was achieved; they were then
treated successfully with proton beam radiotherapy [21].
One should also add that in the case of solitary metastasis,
plaque radiotherapy can be successfully used if EBRT fails
[18]. Shields et al. [18] advocate this technique because of
its short treatment time (3–4 days), unlike the 3–4 weeks
needed for EBRT treatment. However, plaque radiotherapy
can be applied only to inpatients whereas EBRT is used for
outpatients.
The total dose recommended in the literature is not uni-
form and varies from 21 Gy in seven fractions to 40 Gy in 14
fractions [4,6,15,19]. Both total dose and dose per fraction
should be considered in assessing the risk of treatment com-
plications. Four of five radiation-induced complications
have been seen in our series with doses above 35.5 Gy.
In our experience, cataract was infrequent and was found
in only three of 78 treated eyes. Nineteen eyes were treated
without any lens-sparing technique. This low figure is likely
to be explained by a high number of early deaths, given the
rather long delay between therapy and radiation-induced
cataract. In any case attempts should be made whenever
possible to spare the lens. We did not observe any case of
dry eye syndrome. Admittedly, it was not possible to retro-
spectively estimate the proportion of lacrimal glands which
were completely or partially irradiated. Additionally, the
rather low doses and the relatively poor survival rates are
possible explanations for the absence of dry eye syndrome
in our study [12].
In our series, 38% of patients suffered from bilateral syn-
chronous CM. If the contralateral eye was not primarily
irradiated, metachronous metastases occurred in three out
of 26 patients, whereas none were observed when bilateral
irradiation was given (0/10). On the basis of these results
and contrary to the results of Ratanatharathorn et al. [14], it
seems reasonable to recommend bilateral irradiation when-
ever CM are to be treated, given the lack of contralateral
complication and technical ease of this RT technique.
The difference in survival varies according to the site of
the primary lesion and only reflects the natural history of
each tumour site. In our experience the differences were
significant in favour of breast cancer patients.
5. Conclusions
Radiation therapy is an efficient and safe palliative treat-
ment for choroidal metastases and helps the preservation of
vision and thus the quality of life in a group of patients with
an almost uniformly fatal prognosis. Moderate doses (.35.5
Gy) of radiation with a conventional fractionation (2–2.5
Gy/fraction) should be used. We feel it appropriate to
recommend bilateral irradiation even in unilateral uveal
involvement. Whenever possible, a lens-sparing technique
should be used.
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